Excess Body Weight and Gastrointestinal Cancer Risk.
Adiposity
Biliary cancer
Colorectal cancer
Esophageal cancer
Gall bladder cancer
Gastric cancer
Hepatocellular carcinoma
Malignancy
Neoplasm
Obesity
Overweight
Pancreatic cancer
Tumor
Journal
Visceral medicine
ISSN: 2297-4725
Titre abrégé: Visc Med
Pays: Switzerland
ID NLM: 101681546
Informations de publication
Date de publication:
Aug 2021
Aug 2021
Historique:
received:
15
12
2020
accepted:
23
02
2021
entrez:
20
9
2021
pubmed:
21
9
2021
medline:
21
9
2021
Statut:
ppublish
Résumé
Excess body weight (EBW), defined as a body mass index (BMI) ≥25 kg/m EBW is causally associated with colorectal, esophageal (adenocarcinoma), gastric (cardia), pancreatic, biliary and hepatocellular cancer. EBW when combined with tobacco smoking, risky alcohol use, or diabetes can act synergistically to cause gastrointestinal cancer. In recent years, more and more young adults (20-40 years old) were diagnosed with EBW-associated neoplasms. People with EBW should be encouraged to join cancer screening programs. Keeping a healthy weight is a major public health concern and reduces the risk of cancer.
Sections du résumé
BACKGROUND
BACKGROUND
Excess body weight (EBW), defined as a body mass index (BMI) ≥25 kg/m
SUMMARY
CONCLUSIONS
EBW is causally associated with colorectal, esophageal (adenocarcinoma), gastric (cardia), pancreatic, biliary and hepatocellular cancer. EBW when combined with tobacco smoking, risky alcohol use, or diabetes can act synergistically to cause gastrointestinal cancer. In recent years, more and more young adults (20-40 years old) were diagnosed with EBW-associated neoplasms. People with EBW should be encouraged to join cancer screening programs.
KEY MESSAGES
CONCLUSIONS
Keeping a healthy weight is a major public health concern and reduces the risk of cancer.
Identifiants
pubmed: 34540941
doi: 10.1159/000515444
pii: vis-0037-0261
pmc: PMC8406359
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
261-266Informations de copyright
Copyright © 2021 by S. Karger AG, Basel.
Déclaration de conflit d'intérêts
The author has no conflicts of interest to declare.
Références
Am J Epidemiol. 2013 Feb 15;177(4):333-42
pubmed: 23355498
World J Oncol. 2019 Feb;10(1):10-27
pubmed: 30834048
Ann Surg. 2019 Jan;269(1):95-101
pubmed: 28938270
Gastroenterology. 2017 May;152(6):1319-1328.e7
pubmed: 28147224
Am J Gastroenterol. 2020 Jul;115(7):1103-1109
pubmed: 32618661
Front Oncol. 2020 May 29;10:823
pubmed: 32547950
Cancer Epidemiol. 2015 Dec;39 Suppl 1:S34-45
pubmed: 26205840
Diabetes Metab Res Rev. 2016 Jan;32(1):63-72
pubmed: 26111736
Jpn J Clin Oncol. 2014 Sep;44(9):783-91
pubmed: 24951830
CA Cancer J Clin. 2018 Jan;68(1):31-54
pubmed: 29160902
Arch Intern Med. 2009 Apr 27;169(8):764-70
pubmed: 19398688
PLoS Med. 2020 Nov 13;17(11):e1003431
pubmed: 33186354
Lancet. 2020 Mar 7;395(10226):785-794
pubmed: 31492501
CA Cancer J Clin. 2019 Mar;69(2):88-112
pubmed: 30548482
J Diabetes Investig. 2017 May;8(3):397-410
pubmed: 28349643
Cancer Epidemiol Biomarkers Prev. 2015 Oct;24(10):1516-22
pubmed: 26215293
Br J Cancer. 2011 Dec 6;105 Suppl 2:S77-81
pubmed: 22158327
Visc Med. 2020 Jun;36(3):175-181
pubmed: 32775347
Eur J Cancer Prev. 2018 May;27(3):205-212
pubmed: 29489473
Pancreas. 2016 Feb;45(2):311-6
pubmed: 26646264
Cancer. 2017 Oct 15;123(20):4022-4030
pubmed: 28736986
Gastric Cancer. 2020 May;23(3):382-390
pubmed: 31853749
Metabolism. 2019 Mar;92:121-135
pubmed: 30445141
Cancer. 2019 Dec 1;125(23):4210-4223
pubmed: 31490550
Gastroenterology. 2017 Oct;153(4):1006-1017.e5
pubmed: 28711626
Cancer Biol Med. 2020 Feb 15;17(1):181-198
pubmed: 32296585
Gut. 2019 Oct;68(10):1820-1826
pubmed: 31097539
Am J Gastroenterol. 2018 Oct;113(10):1494-1505
pubmed: 30177781
Surgery. 2019 Oct;166(4):547-555
pubmed: 31331685
J Diabetes Investig. 2020 Jan;11(1):55-61
pubmed: 31267699
PLoS One. 2018 Aug 23;13(8):e0202555
pubmed: 30138391
Lancet Public Health. 2019 Mar;4(3):e137-e147
pubmed: 30733056